Eton Pharmaceuticals (ETON) Cash from Investing Activities (2020 - 2025)
Eton Pharmaceuticals (ETON) reported Cash from Investing Activities of -$49000.0 for Q4 2025, up 99.87% on a YoY basis from -$24515.8 in Q4 2024, and up 82.75% sequentially from -$284000.0 in Q3 2025.
Eton Pharmaceuticals (ETON) Cash from Investing Activities (2020 - 2025) Analysis & Trends
Eton Pharmaceuticals (ETON) has 6 years of Cash from Investing Activities data on file, last reported at -$49000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Investing Activities rose 99.87% year-over-year to -$49000.0; the trailing twelve-month figure through Dec 2025 stood at -$333000.0 (up 99.17% YoY), and the FY2025 full-year result was -$333000.0, up 99.17% from the prior year.
- Cash from Investing Activities climbed to -$49000.0 in Q4 2025, from -$284000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$2000.0 in Q3 2021 to a low of -$38.1 million in Q4 2024.
- A 5-year average of -$4.3 million and a median of -$761000.0 in 2022 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities slumped 99900.0% in 2022 and jumped 99.87% in 2025, its largest moves.
- Tracing ETON's Cash from Investing Activities over 5 years: stood at -$3.3 million in 2021, then jumped by 99.63% to -$12000.0 in 2022, then sank by 6358.33% to -$775000.0 in 2023, then tumbled by 4820.26% to -$38.1 million in 2024, then surged by 99.87% to -$49000.0 in 2025.
- Business Quant data shows ETON's Cash from Investing Activities at -$49000.0 in Q4 2025, -$284000.0 in Q3 2025, and -$38.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.82 Bn | 87.96 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 36.03 Bn | 32.29 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.48 Bn | 30.54 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.50 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.02 Bn | 20.86 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.43 Bn | 18.63 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.46 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.73 Bn | 12.30 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Eton Pharmaceuticals | 1.14 Bn | 1.12 Bn | 13.10 Mn | -49,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -49,000.00 |
| Dec 31, 2025 | -49,000.00 |
| Sep 30, 2025 | -284,000.00 |
| Sep 30, 2025 | -284,000.00 |
| Dec 31, 2024 | -38.13 Mn |
| Dec 31, 2024 | -38.13 Mn |
| Mar 31, 2024 | -1.88 Mn |
| Mar 31, 2024 | -1.88 Mn |
| Dec 31, 2023 | -775,000.00 |
| Dec 31, 2023 | -775,000.00 |
| Dec 31, 2022 | -12,000.00 |
| Dec 31, 2022 | -12,000.00 |
| Sep 30, 2022 | -2.00 Mn |
| Sep 30, 2022 | -2.00 Mn |
| Jun 30, 2022 | -761,000.00 |
| Jun 30, 2022 | -761,000.00 |
| Mar 31, 2022 | -15,000.00 |
| Mar 31, 2022 | -15,000.00 |
| Dec 31, 2021 | -3.25 Mn |
| Dec 31, 2021 | -3.25 Mn |